Google
MRVI Stock Price & Analysis — Maravai Lifesciences Holdings Inc (Healthcare >> Biotechnology)
MRVI FAQ
What is MRVI's ROE?
Maravai Lifesciences Holdings Inc reports a Return on Equity (ROE) of -49.42%.
What is MRVI's dividend yield?
Maravai Lifesciences Holdings Inc offers a dividend yield of 0.00%.
What is MRVI's Quality Score?
Our AI rates MRVI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MRVI?
Our AI Timing Score for MRVI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MRVI belong to?
Maravai Lifesciences Holdings Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
MRVI AI Analysis Summary
Our AI summary for MRVI: Maravai Lifesciences Holdings Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -49.42%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 6.43
Price
0.01
(0.16%)
Day Change
|
|
|---|
MRVI, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 6.43 |
| PBV / Sector |
6.42 / 44,022.72
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
16.62 M
GREAT
|
| Average 1W Daily Value |
10.21 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:33 |
| Symbol | MRVI |
| Name | MARAVAI LIFESCIENCES HOLDINGS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 147.51 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,368.17 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10770 Wateridge Circle, San Diego, CA, United States, 92121
Phone: 858 546 0004
Website: https://www.maravai.com
Employees: 416
Sector: Healthcare >> Biotechnology
Description: Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap